Got 90 seconds? Then listen to Kazia Therapeutics CEO and Executive Director Dr. James Garner tell us about his AusBiotech Invest presentation and the company’s recent capital raising.

Kazia Therapeutics (ASX:KZA) is an oncology focused drug developer with a particular focus on difficult-to-treat brain cancers.

The company’s lead drug candidate, GDC-0084 aims to deliver therapies across the blood brain barrier, the body’s natural mechanism to protect the brain from foreign agents. Kazia also has a phase I drug candidate to treat ovarian cancer, called Cantrixil.

Both GDC-0084 and Cantrixil have been granted ‘orphan drug’ designation by the US Food and Drug Administration, which provides benefits such as tax breaks and seven-year marketing exclusivity.

We caught up with Dr. James Garner at the 2019 AusBiotech event and gave him 90 Seconds to tell us more about the company.

Have a good idea for our next 90 Seconds With segment? Email us at tv@stockhead.com.au.